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The lymphatic vascular system is an open-ended network of 
endothelial cell–lined vessels that works to transport extravasated 
tissue fluid, proteins, metabolites, and cells from the interstitial 
space back to the circulatory system via the thoracic duct (1). Lym-
phatic capillaries, which lack a basement membrane, are made of 
overlapping endothelial cells that adhere to the extracellular matrix 
through fibrillin-rich, pressure-sensing anchoring filaments. 
Under conditions of interstitial edema, lymphatic endothelial 
cells (LECs) stretch apart to collect excess fluid and large proteins. 
Propulsion of lymph fluid into the larger collecting lymph vessels 
is largely dependant on the vascular smooth muscle contractions 
of the upper circulatory trunks. Lymphatic vessels also mediate 
lipid uptake from the gut and transport white blood cells and anti-
gen-presenting cells to lymphoid organs. Moreover, the lymphatic 
system plays important roles in pathological conditions such as 
inflammation, scarring, and tumor metastasis (2–5). Despite its 
central roles in both normal and disease physiology, our under-
standing of the development and molecular regulation of the lym-
phatic vascular system lags far behind that of the parallel blood 
vascular system (6, 7).
In recent years, advanced genetic engineering techniques have 
supported the concept that during development, LECs bud from 
veins to form primary lymph sacs, which then proliferate and 
sprout into the periphery to form lymphatic capillaries and ves-
sels. One of the earliest molecular markers distinguishing venous 
endothelial cells with a lymphatic bias is the transcription factor 
prospero-related homeobox 1 (Prox1) (8). Prox1 is expressed in a 
polarized fashion in the venous endothelium and serves as a mas-
ter switch for establishing LEC competence (9). Knockout mice 
for Prox1 show ablated budding and sprouting of primary lymph 
sacs and die at E14.5 with severe edema (10). Genetic mouse mod-
els with loss of VEGFC signaling also develop severe interstitial 
edema due to failed lymphatic budding and migration (11). The 
eventual separation of lymphatic vessels from the venous circula-
tion is largely mediated by the tyrosine kinase Syk and adaptor 
protein SLP76. Mice with homozygous deletions for the genes 
encoding these proteins develop arteriovenous shunts and abnor-
mal lymphatic-venous connections (12). Finally, several genes have 
been implicated in the later stages of lymphatic vessel patterning 
and postnatal maturation, including podoplanin (13), neuropil-
lin2 (14), FoxC2 (15), and angiopoietin-2 (16). While a few of these 
gene products, such as VEGFC and angiopoietins, show promise as 
potential targets for the stimulation, inhibition, or modulation of 
lymphangiogenesis and lymphatic function in lymphedematous 
tissues or tumors of adult animals (17), there remains a crucial 
need to identify additional genetic and pharmacologically trac-
table targets that regulate the development and function of the 
lymphatic vascular system (1, 18).
Adrenomedullin (AM) is a multifunctional, 52-aa peptide vaso-
dilator that is pathologically elevated in a variety of tumors (19) 
and cardiovascular conditions (20). In addition to its function as 
a potent vasodilator, AM is also recognized as an important vascu-
lar factor involved in angiogenesis and endothelial cell prolifera-
tion. AM treatment potently induces the proliferation, migration, 
and capillary tube formation of cultured HUVECs and directly 
promotes endothelial cell growth and survival through activa-
tion of MAPK/ERK downstream signaling pathways (21–26). 
Similar results have been recapitulated in vivo through the use 
of a hind-limb ischemia model (27) and a differentiated ES cell 
culture model (28) in which AM treatment promotes an angio-
genic response. Taken together, these data demonstrate that AM 
signaling in the blood vasculature plays an important role in vessel 
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development, remodeling, and function; however, its role in the 
lymphatic vascular system has yet to be addressed.
AM binds and signals through a GPCR, calcitonin receptor–like 
receptor (calcrl, gene; CLR, protein). The ligand-binding affinity of 
CLR (and other class II GPCRs) can be changed via receptor inter-
action with a class of single-pass transmembrane proteins called 
receptor activity–modifying proteins (RAMPs) (29). Since the AM 
receptor and the 3 mammalian RAMPs are highly expressed in 
the vasculature, this paradigm of cell signaling is being explored 
pharmaceutically for the potential treatment of conditions such 
as migraine (30), pulmonary hypertension (31), and other cardio-
vascular disorders (32), and for the modulation of cancer progres-
sion (33). However, determining the functional significance of 
AM signaling on the vasculature during embryogenesis and adult-
hood remains an area of intense investigation that we here address 
with genetically engineered animals that either lack AM, calcrl, or 
RAMP2 globally or that lack calcrl specifically in endothelial cells.
Results
AM–/–, calcrl–/–, and RAMP2–/– embryos failed to survive and devel-
oped severe interstitial edema without hemorrhage by mid-gesta-
tion (Figure 1, A, D, and G). Histology of the AM–/–, calcrl–/–, and 
RAMP2–/– embryos confirmed the presence of extreme interstitial 
edema and the notable absence of hemorrhagic plaques (Figure 1, 
B, C, E, F, H, and I). The onset of edema between the different lines 
was temporally staggered by approximately 24 hours, after which 
all null embryos were found dead 1–2 days later. The delay in phe-
notypic onset in RAMP2–/– embryos suggests that some compensa-
tory signaling for AM, perhaps through a RAMP3-CLR complex, 
may still exist during embryonic development. However, our previ-
ous observations that RAMP3-null mice survive to adulthood with 
few phenotypic defects (34) demonstrates that RAMP3 is unable 
to fully replenish RAMP2-mediated AM signaling in vivo. More-
over, we found that RAMP2–/– embryos displayed developmental 
defects remarkably similar to those we have previously described 
for AM–/– and calcrl–/– mice (35, 36) (Supplemental Figure 1; sup-
plemental material available online with this article; doi:10.1172/
JCI33302DS1). Therefore, this conserved phenotypic series from 
3 independent knockout mouse lines provides compelling genetic 
evidence to define CLR and RAMP2 as the receptor components 
required for AM signaling during embryogenesis.
Generalized edema and mid-gestation lethality can be caused by 
a multitude of developmental defects during embryogenesis. To 
determine whether the loss of AM signaling in vascular endothelial 
cells could account for the embryonic edema and/or lethality of 
global AM–/–, calcrl–/–, and RAMP2–/– embryos, we generated mice 
with a conditional allele for the calcrl gene. Using the Cre-loxP gene 
targeting strategy, we generated homozygous floxed mice for the 
calcrl gene and confirmed correct gene targeting by Southern blot 
and genomic PCR (Figure 2, A–C). Importantly, our gene targeting 
approach ensured that the loxP sites flanked the same genomic 
regions as those deleted in the original calcrl-knockout mouse 
(36), thereby eliminating the possibility of generating allelic phe-
notypes. Homozygous floxed calcrl mice (calcrlFlox/Flox) appeared 
normal, bred well, and had levels of calcrl gene expression that were 
indistinguishable from those of wild-type animals (Figure 2D).
As shown in the schematic of Figure 2E, we bred the calcrlFlox/Flox 
mice to mice that were heterozygous for the calcrl gene knockout 
and positive for expression of Cre recombinase in endothelial cells 
via expression of a Tie2-Cre transgene (37). By breeding onto a 
calcrl+/– genetic background, we ensured robust excision of a single 
floxed allele and thereby reduced the incidence of mosaic cellular 
excision. Importantly, calcrl+/– mice are born at the expected Men-
delian ratio and survive to adulthood with few phenotypic defects 
Figure 1
Phenotypic series of AM signaling–null mice. Genetic deletion of genes responsible for AM signaling results in a phenotypic series of null 
mice with generalized edema and lethality at mid-gestation. (A) Generalized interstitial edema, without hemorrhage, was observed throughout 
calcrl–/– embryos at E12.5. Similar edema was present by E13.5 in AM–/– embryos (D) and by E14.5 in RAMP2–/– embryos (G). Edema was not 
observed 1 day before onset, and no viable embryos were recovered 1–2 days after edema onset. H&E-stained transverse sections of wild-type 
littermates (B, E, and H) and calcrl–/–, AM–/–, and RAMP2–/– (C, F, and I) embryos at E12.5, E13.5, and E14.5, respectively. Arrowheads indicate 
interstitial fluid accumulation. Original magnification, ×10 (A, D, and G); ×20 (B, C, E, F, H, and I).
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(34). The resulting mice from the Cre-loxP breeding strategy, 
calcrlLoxP/–Tie2Cre+, were therefore global heterozygotes for calcrl 
and lacked calcrl expression specifically in endothelial cells as early 
as E10.5. We noticed a slight reduction in the Mendelian distri-
bution of calcrlFloxP/–Tie2Cre– mice (Figure 2F), which is consistent 
with the leakiness of the Tie2Cre transgene in the female germline 
leading to global calcrl excision and embryonic lethality (37). Con-
sistently, the calcrlLoxP/–Tie2Cre+ mice were embryonic lethal and 
developed extreme interstitial edema without hemorrhage, some-
times as early as E13.5 (Figure 2, F and G). However, in contrast 
to the global calcrl–/– mice, which die by E13.5, the onset of edema 
and eventual demise of the calcrlLoxP/–Tie2Cre+ mice was often sub-
stantially delayed to approximately E16.5, 3–4 days later than the 
global calcrl–/– mice. Thus, we conclude that endothelium-specific 
deletion of calcrl prolonged the survival of AM signaling mutants 
during development but nevertheless resulted in generalized 
edema without hemorrhage similar to that in global calcrl-knock-
out mice. These data demonstrate that the cellular basis of the 
embryonic edema and eventual lethality in AM signaling mutant 
mice is due to loss of AM signaling in endothelial cells.
Despite the well-established role for AM in maintaining vascular 
permeability (38, 39), we very rarely observed blood hemorrhage, 
and only occasionally in embryos that were visibly deteriorated or 
near death. For example, of 72 wild-type embryos, 7 (9.7%) exhib-
ited some form of visible hemorrhage, and only 4 of 56 RAMP2–/– 
littermates (7.1%) showed evidence of hemorrhage. Thus, the 
Figure 2
Generation and characterization of 
conditional calcrl line. (A) Schematic 
diagram depicting strategy used for 
generation of a floxed calcrl allele by 
gene targeting. The top figure shows the 
endogenous wild-type calcrl allele. The 
targeting vector was designed so that 
loxP sites would flank the same exons 
that were deleted in the calcrl global 
knockout (36). The third line depicts the 
targeted calcrlFlox allele, and the fourth 
line depicts the calcrlLoxP allele after 
Cre-mediated excision. Primers used for 
isolation of correctly targeted ES cells 
and for routine genotyping are indicated 
by small arrows. (B) Correctly targeted 
ES cells were confirmed by Southern 
blot analysis using the probe depicted in 
A. (C) PCR genotyping for the calcrlFlox 
allele. (D) Quantitative RT-PCR was 
performed on RNA isolated from lungs 
and hearts of wild-type and homozygous 
calcrlFlox/Flox mice and revealed no signifi-
cant differences in the expression of the 
calcrlFlox allele before Cre-mediated exci-
sion. (E) Schematic representation of 
breeding scheme used to generate mice 
with calcrl expression deleted specifically 
in endothelial cells by use of the Tie2Cre 
transgene. (F) Results of cross demon-
strate that no viable calcrlLoxP/–Tie2Cre+ 
mice were found beyond E16.5. (G) 
Compared with calcrlLoxP/+Tie2Cre+ con-
trol littermates, the calcrlLoxP/–Tie2Cre+ 
mice displayed remarkable hydrops 
without hemorrhage, which phenocopied 
the global calcrl–knockout phenotype, 
yet often occurred substantially later, at 
E16.5. Original magnification, ×10.
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remarkable lack of embryonic hemorrhage in the AM–/–, calcrl–/–, 
and RAMP2–/– embryos suggested to us that the developing blood 
vasculature remained largely intact during embryonic develop-
ment. Moreover, presence of high-MW proteins in the intersti-
tial fluid confirmed that the null mice suffered from embryonic 
lymphedema as opposed to osmotic imbalance (Supplemental 
Figure 2). Thus, based on the absence of blood hemorrhage, the 
presence of embryonic lymphedema, and the fact that the edema-
tous phenotype of AM signaling–null mice more closely 
resembled that of other mouse models with defects in lym-
phangiogenesis (10, 11, 14) rather than defects in blood 
vascular permeability (40–43), we hypothesized that AM 
signaling might be principally important for orchestrating 
normal lymphangiogenesis.
First, we demonstrated that AM, calcrl, and RAMP2 are 
expressed in adult lymphatic vessels at levels similar to 
those observed in whole embryonic RNA extracts (Fig-
ure 3A). To determine whether AM was also expressed 
in lymphatic vessels during embryonic development, we 
made use of an EGFP that was inserted at the initiator 
methionine of the endogenous AM gene by homologous 
recombination and serves as a biological marker of AM 
gene expression in AM+/– and AM–/– mice (35). As shown in 
Figure 3B, AM was expressed in endothelial cells lining the 
jugular vein and budding lymph sac at E12.5, which cor-
relates with the earliest stages of lymphatic vascular devel-
opment. Interestingly, we noticed that the pattern of AM 
expression in the jugular vein was often polarized toward 
the developing lymph sac, similar in pattern to that of the 
master transcriptional regulator of lymphatic specifica-
tion, Prox1 (9). We therefore conclude that the expression 
of genes required for AM signaling is robust in adult and 
developing LECs and is similar in pattern to that of Prox1 
during embryogenesis.
We next performed immunohistochemistry using LEC markers 
to determine whether AM signaling was required for the initial 
formation of jugular lymph sacs. Distinct lymph sacs were pres-
ent in wild-type, RAMP2–/–, and AM–/– embryos by E13.5 (Figure 4, 
A–C) and stained positively for PECAM and the lymphatic-specific 
makers VEGFR3 and Prox1, indicating normal lymphatic differ-
entiation from venous vasculature. Similar results were observed 
in calcrl–/– embryos (data not shown). We also identified distinct 
Figure 3
AM signaling components are expressed in adult and developing lymphatic 
vessels. (A) Isolated adult lymphatic vessels express AM, calcrl, and RAMP2 
at levels similar to whole embryo RNA extracts. Adult mouse lymphatic ves-
sels were identified by the uptake of Evans blue dye injected into the hind paw 
and were subsequently microdissected for RNA isolation. Expression of AM, 
calcrl, and RAMP2 mRNAs in these vessels was comparable to mRNA levels 
in E10–E12.5 embryos by quantitative RT-PCR. n > 4 samples, analyzed twice 
in triplicate. (B) To determine whether LECs express AM during development, 
we used an EGFP that serves as a biological marker of AM gene expression in 
AM gene–targeted mice (35). Unstained transverse sections through the jugu-
lar region of an E12.5 AM+/– embryo show that AM is expressed in endothelial 
cells of both the jugular vein (V) and jugular lymph sac (LS) (arrows). Note the 
polarized expression of AM in the progenitor cells, which will eventually migrate 
to form the lymph sac. Original magnification, ×200.
Figure 4
Differentiated lymph sacs and dermal lymphatics are present in AM signaling–null embryos. Immunofluorescent staining of transverse sections 
through the jugular region (A–C) and sagittal sections through the skin (D and E) of E13.5 embryos. (A) Endothelial cells of lymph sacs from wild-
type mice at E13.5 expressed VEGFR3 (red) and Prox1 (green). (B) Similar staining was observed in the lymph sacs of RAMP2–/– littermates. 
Nuclei stained with Hoechst are indicated in blue (A and B). (C) Prox1 (green) was also correctly coexpressed with PECAM (red) in lymph sacs of 
AM–/– embryos. (D and E) Dermal lymphatics (arrows) were present in wild-type (D) and RAMP2–/– (E) littermates at E14.5 as shown by VEGFR3 
(red) and PECAM (green) staining. Dermal blood endothelium (arrowheads) expresses PECAM but not VEGFR3. n > 6 embryos per genotype. 
A, carotid artery, A; S, skin. Original magnification, ×200. Scale bar: 100 μM.
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VEGFR3-positive vessels in the skin of RAMP2–/– embryos (Fig-
ure 4, D and E), indicating that the development of the dermal 
lymphatic vasculature remains intact in AM signaling–mutant 
mice. From these findings, we conclude that AM signaling is not 
required for the early stages of lymphangiogenesis, including dif-
ferentiation and migration of LECs and the formation of primary 
lymph sacs and dermal lymphatic vessels.
Although immunohistochemistry revealed the presence of 
lymph sacs in the AM signaling–null mouse models, we noticed 
from histological sections that the jugular lymph sacs appeared 
strikingly smaller than those of litter-matched wild-type embryos 
(Figure 5, A–D). To confirm the apparent hypoplasia of the lymph 
sacs, we used computerized morphometry to calculate lymph sac 
area and found that all null mice showed significantly reduced 
lymph sac area compared with wild-type embryos at E13.5 (Figure 
5, E–G). Thus, despite excessive interstitial lymphedema (which 
would normally cause lymphatic vessel distension), the lymph sacs 
of the AM signaling–null embryos remained significantly smaller 
than wild-type lymph sacs, suggesting either a functional failure of 
the early lymphatics to take up extravasated fluid or an abnormal-
ity in LEC growth and proliferation.
To determine whether an ultrastructural defect in LECs could 
lead to a functional failure of lymphatic vessels during develop-
ment, we performed transmission electron microscopy of RAMP2–/– 
and wild-type mice at E14.5. LECs of the jugular lymphatic vessels 
in wild-type mice displayed typical features, including overlapping 
cell-cell contacts (Figure 6A, arrowheads), electron-dense tight 
junctions (Figure 6, B and C, arrows), and anchoring filaments 
Figure 5
Loss of AM signaling results in hypoplastic lymph sacs. Lymph sacs of calcrl–/–, AM–/–, and RAMP2–/– embryos were significantly smaller than 
those of their WT littermates at E13.5. (A–D) H&E-stained sections through transverse sections of the jugular lymph sacs of wild-type (A), calcrl–/– 
(B), AM–/– (C), and RAMP2–/– (D) embryos at E13.5. Note the remarkable decrease in size of lymph sacs relative to jugular vein and carotid artery 
in the AM signaling–mutant embryos, despite massive interstitial edema. (E–G) Quantitation of lymph sac area, normalized to jugular vein area 
in calcrl–/– (E), AM–/– (F), and RAMP2–/– (G) embryos (black bars) and their wild-type littermates (gray bars) at E13.5. E, F, and G have different 
scales. n > 6 embryos per genotype. Error bars indicate SEM. P values were determined using Student’s s test. Original magnification, ×200.
Figure 6
LECs of RAMP2–/– mice are thin with otherwise normal ultrastruc-
tural features. Transmission electron microscopy of wild-type 
(A–C) and RAMP2–/– (D–F) lymph sacs at E14.5. In general, the 
LECs of RAMP2–/– mice appeared significantly thinner than those 
of wild-type littermates. Although obvious edema was present in 
the interstitial space surrounding both the veins and lymph sacs 
in RAMP2–/– embryos, endothelial cells could be followed continu-
ously around both vessel types, without obvious breaks or gaps. 
Other typical ultrastructural features of lymphatic vessels were 
identified in both wild-type and RAMP2–/– mice including: overlap-
ping contacts (arrowheads), tight junctions (arrows), and anchor-
ing filaments (A). Occasionally necrotic endothelial cells (**) 
were observed in RAMP2–/– mice, but the associated tight junc-
tions remained structurally intact. n = 2 wild-type and 3 RAMP2–/–. 
L; lumen. Scale bar: 1 μm.
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(Figure 6A). Wild-type lymphatic vessels at this stage of develop-
ment also lacked a basement membrane and lymphatic smooth 
muscle cells (see also Supplemental Figure 3), thus precluding 
the possibility that failure of smooth muscle recruitment could 
account for the lymphatic phenotypes observed in the AM sig-
naling–null mice. In RAMP2–/– mice the overlapping cell-cell con-
tacts, tight junctions, and anchoring filaments remained intact 
(Figure 6, D and E). Occasionally, necrotic LECs were observed 
in RAMP2–/– mice (Figure 6F), but the tight junctions neverthe-
less remained intact. Consistently, we found that RAMP2–/– LECs 
appeared markedly thinner than wild-type LECs. Based on these 
data, we found no substantial evidence to suggest that the lym-
phatic vasculature of the RAMP2–/– mice would fail to function 
due to ultrastructural abnormalities.
To determine whether the smaller lymph 
sacs of AM signaling–mutant mice could be 
due to abnormal endothelial cell proliferation, 
we used a BrdU incorporation assay to count 
proliferating cells in both lymph sacs and 
adjoining jugular veins. In AM–/–, RAMP2–/–, 
and calcrl–/– embryos, there were significantly 
fewer proliferative endothelial cells in the 
lymph sacs; the proliferation of the venous 
endothelial cells was somewhat reduced in 
the null mice, but the difference compared 
with wild-type mice was not statistically sig-
nificant (Figure 7, A–C). Taken together these 
results demonstrate that lack of AM signaling 
during embryonic development leads to a spe-
cific reduction in lymphatic, but not venous, 
endothelial cell proliferation.
To confirm that loss of AM signaling prefer-
entially affected the development of the lym-
phatic versus blood vascular system, we used 
whole mount immunohistochemistry for 
VEGFR3 or PECAM followed by 3D optical 
projection tomography (OPT) (44) in RAMP2–/– 
mice. While we found no obvious differ-
ences in the morphological development of 
the blood vascular system between wild-type 
and knockout mice (Figure 7, D and E), we 
did observe extraordinary differences in the 
jugular lymphatic trunks (Figure 7, F and G, 
large yellow arrows). While wild-type mice had 
large, well-formed jugular lymphatic trunks, 
the same vessels were essentially absent in the 
RAMP2–/– littermates (Figure 7 and Supple-
mental Movies 4 and 5). Notably, the retroper-
itoneal lymph vessel (which develops into the 
thoracic duct) and the dermal lymphatic ves-
sels of RAMP2–/– embryos appeared indistin-
guishable from those of wild-type littermates 
(Figure 7, F and G, small red arrows, and Fig-
ure 4, D and E). Therefore, we conclude that 
AM signaling is preferentially required for 
the normal proliferation and morphological 
integrity of the jugular lymphatic vessels dur-
ing the later stages of lymphangiogenesis.
To determine the downstream signal-
ing cascades that are associated with the 
enhanced activity of AM signaling in LEC proliferation, we made 
use of 2 distinct endothelial cell lines: HUVECs and human der-
mal lymphatic microvascular endothelial cells (herein referred to 
as HMVEC-dLy). Histology and immunohistochemistry revealed 
that HMVEC-dLys and HUVECs differed in cellular morphology 
and their expression of Prox1, a finding that is consistent with the 
characterization of the former as lymphatic endothelial cells (Fig-
ure 8A). Stimulation of HUVECs and HMVEC-dLys with VEGFA 
resulted in an expected and dose-dependant increase in cellular 
proliferation that did not differ significantly between the 2 cell 
lines (Figure 8B). In contrast, while AM elicited a modest yet sig-
nificant increase in HUVEC proliferation, the proliferative effects 
of AM on HMVEC-dLys were substantially more robust and signif-
icantly different from the effects of AM on HUVEC proliferation at 
Figure 7
AM signaling is required for the proliferation and growth of jugular lymphatic vessels during 
embryonic development. (A–C) The percentage of proliferating cells relative to total cells was 
determined in the jugular vein and neighboring jugular lymph sac of wild-type (gray bars) and 
calcrl–/–, AM–/–, and RAMP2–/– (black bars, A–C, respectively) littermate embryos. Percent 
proliferative cells was defined as the number of BrdU-positive endothelial cells divided by 
the total number of endothelial cells in each vessel. Error bars indicate SEM. *P = 0.01 for 
calcrl–/– (A), P = 0.004 for AM–/– (B), and P = 0.01 for RAMP2–/– (C); Student’s t test. n > 6 ani-
mals per genotype. (D and E) Whole mount immunofluorescence of developing vasculature 
identified by PECAM staining and visualized by 3D OPT of wild-type (D) and RAMP2–/– (E) 
littermate embryos at E13.5. (F and G) Whole mount immunofluorescence of developing 
lymphatic vasculature identified by VEGFR3 staining and visualized by 3D OPT of wild-type 
(F) and RAMP2–/– (G) littermate embryos at E14.5. Compare the presence of well-formed 
jugular lymph sacs in the wild-type embryo (yellow arrows in F) with the relative lack of jugular 
lymphatic vessels in the RAMP2–/– littermate (G). Note that the retroperitoneal lymph vessel 
(red arrows) and dermal lymphatic vessels (green asterisks) of RAMP2–/– mice appear normal 
compared with those of wild-type embryos. Three embryos from 2 different litters were stained 
for PECAM and VEGFR3. The online supplemental data contains movies for enhanced, high-
resolution, 3D viewing (Supplemental Figures 4 and 5). Scale bar: 2,000 μM.
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10 nM (Figure 8C). Direct cell count determinations verified that 
HMVEC-dLys treated with 10 nM AM for 48 hours showed 2-fold 
more proliferation than similarly treated HUVECs (81% vs. 37% 
more than control, P < 0.01; data not shown).
To determine the downstream signaling pathways associated 
with the effects of AM signaling on HMVEC-dLy proliferation, 
we quantitatively assessed the activation of ERK in HUVECs 
and HMVEC-dLys that were treated with 10 nM AM. Using a 
Gaussian fit curve analysis, we found that AM stimulation of 
HMVEC-dLys resulted in approximately twice the overall levels 
of phosphorylated ERK over a 30-minute time course compared 
with HUVECs (Figure 8D). Inhibition of AM-mediated ERK phos-
phorylation by a RAMP2-specific AM inhibitor, AM22–52 (45), and 
by the MAPK inhibitor PD98057 confirmed that ERK activation 
by AM signaling in HMVEC-dLys is mediated through a RAMP2-
CLR receptor complex (Figure 8E). Taken together, these com-
parative studies in cultured endothelial cells demonstrate that 
AM signaling, through a RAMP2-CLR receptor complex, has a 
preferential and enhanced effect on ERK-mediated proliferation 
of HMVEC-dLys compared with HUVECs.
Several comparative transcriptional profiling studies have shown 
enhanced expression of AM signaling genes in lymphatic versus 
blood endothelial cells (46, 47) and lymphedematous versus nor-
mal vasculature (48). Therefore, we hypothesized that the enhanced 
sensitivity of LECs to AM signaling could be due to preferential 
upregulation of the receptor components required for AM signal-
ing. Quantitative RT-PCR for AM, CALCRL, and RAMP2 confirmed 
our assumptions and showed approximately 4-fold higher levels of 
gene expression in cultured HMVEC-dLys compared with HUVECs 
(Figure 9A). Because we had previously observed that the expres-
sion of AM in vivo closely matched the pattern of Prox1 expression 
in the developing lymphatic sacs of E13.5 embryos (Figure 3B), we 
next wanted to determine whether the AM receptor, CALCRL, could 
be a downstream target gene of Prox1. Therefore, we transfected a 
hProx1 expression plasmid into cultured HMVEC-dLys and mea-
sured mRNA production of endogenous LYVE and CALCRL. Con-
sistent with previous studies showing that Prox1 is not required 
for the lymphatic-specific expression of LYVE (10), overexpression 
of Prox1 in HMVEC-dLys did not induce the expression of LYVE 
(Figure 9B). In contrast, overexpression of Prox1 resulted in a 
3-fold increase in endogenous CALCRL expression levels compared 
with empty vector control transfections (Figure 9C). We therefore 
conclude that the expression of genes required for AM signaling is 
preferentially robust in HMVEC-dLys compared with HUVECs and 
furthermore inducible by Prox1.
Discussion
We have performed a comparative phenotypic characterization of 
3 independent gene-knockout models for genes that encode pro-
teins purported to be involved in signaling for AM peptide. The 
remarkable conservation in phenotypes between knockout mice 
with targeted loss of either AM peptide, the GPCR CLR or its 
modifying protein, RAMP2, provides compelling genetic evidence 
to define the receptor components required for AM signaling dur-
Figure 8
AM signaling preferentially mediates enhanced ERK 
activation in HMVEC-dLys compared with HUVECs. 
(A) Cultured HMVEC-dLys and HUVECs are mor-
phologically and genetically distinct cell lines based 
on histology and expression pattern of Prox1. Origi-
nal magnification, ×400. (B) Stimulation of HUVECs 
and HMVEC-dLys with the potent growth factor 
VEFGA resulted in a dose-dependant increase in 
cell proliferation that was not significantly different 
between the 2 cell lines. Data represent averages 
of 4 independent experiments, each performed in 
duplicate. (C) Stimulation of HUVECs and HMVEC-
dLys with AM peptide resulted in a dose-dependant 
increase in cell proliferation that was significantly 
greater in HMVEC-dLys compared with HUVECs. 
*P < 0.05. Data represent averages of 4 indepen-
dent experiments, each performed in duplicate. (D) 
Stimulation of HUVECs and HMVEC-dLys with 10 
nM AM peptide resulted in a significantly greater 
induction of ERK phosphorylation in HMVEC-dLys 
compared with HUVECs over a 30-minute time 
course. *P < 0.03 at 15- and 20-minute time points. 
Data represent averages of 3 independent experi-
ments, each performed in duplicate. (E) Induction of 
ERK activation by AM stimulation in HMVEC-dLys 
was significantly reduced by the RAMP2-specific 
peptide inhibitor AM22-52 and completely blocked by 
the MAPK inhibitor PD98057 (PD). *P < 0.05 com-
pared with untreated; #P < 0.05 compared with AM-
treated. Data represent averages of 3 independent 
experiments, each performed in duplicate.
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ing embryogenesis. The paradigm of RAMP/GPCR signaling offers 
the exciting opportunity to generate pharmacological compounds 
that specifically interact at the RAMP-GPCR interface for modu-
lating the activity of several peptide agonists. As an example, the 
small-molecule compound BIBN4096BS (49) specifically binds to 
RAMP1-CLR complexes to antagonize CGRP activity and is cur-
rently in clinical trials for treatment of migraine (50). Our con-
served phenotypic series of null mouse models suggest that com-
pounds specific to the RAMP2-CLR interface would provide the 
best pharmacological target for modulation of AM activity in vivo.
AM is a secreted peptide vasodilator that is highly expressed 
in blood endothelial cells and induced by hypoxia to promote 
angiogenesis and inhibit vascular permeability (31, 51). Here 
we show that AM and its receptors are more highly expressed in 
HMVEC-dLys under the control of the lymphatic-specific tran-
scriptional regulator Prox1. Therefore, the enhanced level of CLR 
receptor expression disposes LECs to a more robust AM response 
than blood endothelial cells (Figure 10). As a consequence, global 
genetic loss of AM, calcrl, or RAMP2 causes marked and preferen-
tial reduction in the proliferation of LECs of the jugular lymphatic 
vessels. Our current explanation for the cause of edema in these 
mouse models is that lack of lymphatic proliferative signals dur-
ing lymphangiogenesis results in smaller, lower-capacity jugular 
lymphatic vessels that are unable to accommodate the normal 
uptake of extravasated fluid and thus exacerbates massive inter-
stitial edema. It is also worth emphasizing that the precise cause 
of embryonic lethality has yet to be determined.
A multitude of developmental defects during embryogenesis can 
lead to edema and mid-gestation lethality. For example, we cannot 
at this time exclude the possibility that global loss of AM signaling 
might also cause excessive permeability of the blood vasculature, 
contributing to the overall hydrops phenotype. In this regard, our 
data suggest that global loss of AM, calcrl, or RAMP2 results in thin 
vascular smooth muscle coverage of large blood vessels (35, 36) 
(Supplemental Figure 1, E and F). However, based on the absence 
of hemorrhage and the remarkable similarity of our phenotype to 
that of other genetically engineered mouse models with defects in 
lymphangiogenesis (10, 11, 14) (rather than mouse models with 
leaky blood vasculature or thin vascular smooth muscle walls; 
refs. 40–43), we contend that the major contribution to the overall 
hydrops phenotype in AM signaling–null mice comes from the loss 
of gene function in the lymphatic vasculature. We have also shown 
that global loss of AM, calcrl, or RAMP2 results in smaller hearts 
with thin compact zones and ventricular trabeculae (35, 36) (Sup-
plemental Figure 1, A–D), and heart failure can sometimes con-
tribute to embryonic edema. However, since the AM signaling–null 
mice do not suffer from hepatic congestion or bradycardia and 
since the edema is characteristically generalized interstitial edema 
(as opposed to pericardial effusion, which most often accompanies 
embryonic heart failure), we believe that it is unlikely that heart 
failure is the principal cause of embryonic edema.
Our generation and characterization of mice with conditional 
loss of calcrl in vascular endothelial cells further supports our 
interpretation for a principal and essential role for AM signaling 
in endothelial cells during embryonic development. Since expres-
sion of the Tie2Cre transgene precedes the onset of lymphangio-
genesis in embryonic veins and since the Tie2 promoter is active in 
developing LECs (52), it is likely that excision of the calcrl gene also 
occurs robustly in the developing LECs of the calcrlLoxP/–Tie2Cre+ 
mice. However, the Tie2Cre transgene is also expressed in cells of 
the hematopoietic lineage, which have modest expression of AM 
signaling components (53, 54) and have been previously demon-
strated to contribute to lymphatic vascular development (55). 
Therefore, we cannot exclude the possibility that loss of AM sig-
naling in the hematopoietic lineage also contributes to the over-
all phenotype of the calcrlLoxP/–Tie2Cre+ mice. Similarly, we cannot 
exclude the possibility that loss of AM signaling in cardiac struc-
tures derived from Tie2Cre-expressing progenitors (for example, 
mesenchymal cells of the atrioventricular canal and the proximal 
outflow tract) may contribute to the phenotype. Future studies 
with conditional deletion of the calcrl gene exclusively in blood 
endothelial cells, LECs, or hematopoietic cells will help address 
these caveats, but suitable Cre-transgenic mouse lines with exclu-
sive expression of Cre in these cell types must first be generated.
Hypoplastic growth of the lymphatic vasculature during devel-
opment has also been described in mice that lack neuropillin2 (14), 
a coreceptor for the lymphangiogenic growth factor VEGFC. One 
assumption that can be made from these apparently similar phe-
notypes is that VEGFC and AM signaling may interact simulta-
neously to control the proliferation of the developing lymphatic 
vessels during embryogenesis. However, in contrast to the AM 
signaling–null phenotype, loss of neuropillin2 selectively and tran-
siently compromised the proliferation of smaller lymphatic vessels 
and capillaries, but not jugular lymphatic vessels, during develop-
Figure 9
AM signaling genes are preferentially upregulated in LECs via Prox1 
induction. (A) Comparative gene expression analysis for hAM, 
hCALCRL, and hRAMP2 in cultured HUVECs versus LECs, demon-
strating significantly higher levels of gene expression in LECs com-
pared with HUVECs. Data represent averages of 3 independent exper-
iments, each performed in duplicate. (B) As expected, the endogenous 
expression of the lymphatic-specific marker LYVE was not induced by 
transient overexpression of hProx1 in LECs. (C) In contrast, expres-
sion of endogenous CALCRL was potently induced by transient over-
expression of hProx1 in LECs. Data presented in B and C are from 1 
experiment and representative of 3 independent transfections each 
performed in triplicate.
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ment. Together, these results demonstrate that the development of 
small and large lymphatic vessel populations is under the control 
of different lymphangiogenic factors and that these growth factors 
may work autonomously in lymphatic vessels that arise from dif-
ferent progenitor populations.
Our current study and those of others (21–26) show that AM 
signaling directly promotes endothelial cell growth and sur-
vival through activation of MAPK/ERK downstream signaling 
pathways. In contrast, the Sprouty/Spred family of proteins 
mediates an important negative regulation of growth factor– 
and cytokine-induced MAPK/ERK activation. Recently, Tani-
guchi et al. showed that mice with double genetic deletion of 
Spred-1 and -2 develop marked edema and dilated, blood-filled 
lymphatic vessels (56). While the number of blood vessels and 
blood endothelial cells in Spred-1/2–deficient embryos did not 
differ from that in wild-type embryos, the authors found a sig-
nificant increase in the number of LECs and lymphatic vessels 
that was due to abnormal loss of VEGFC/VEGFR-3 inhibition 
and subsequent higher ERK activation. The phenotype of hyper-
plastic lymphatic vascular growth by enhanced ERK activation 
in Spred-1/2–knockout mice stands in notable contrast to our 
AM signaling–null phenotype of hypoplastic lymphatic vascular 
growth caused by decreased ERK activation in HMVEC-dLys. 
Taken together, the comparative findings from the two studies 
are entirely consistent with the notion that the tight control of 
ERK activation by vascular growth factors is essential for the 
controlled proliferation of LECs during development.
Failure or insufficient function of the lymphatic vascular system 
results in disfiguring, disabling, and sometimes life-threatening 
swelling of the limbs, called lymphedema (57), which most often 
occurs as a result of a parasitic filarial infection or secondary to 
surgical removal of lymph nodes, radiation therapy, or infection 
(2). Recent studies have also brought the lymphatic system to the 
forefront as an important route of tumor 
metastasis (3, 6), the major cause for treat-
ment failure and decreased survival in 
cancer patients. Thus, a concerted effort is 
being made to identify new genetic and/
or pharmacological targets for the man-
agement and treatment of lymphedema 
and for inhibiting the metastatic spread 
of cancer cells. Ideally, these treatments 
would improve lymphatic permeability, 
induce the controlled proliferation of the 
existing lymphatic vasculature, or inhibit 
tumor lymphangiogenesis. The elucida-
tion of a previously unrecognized role for 
AM signaling in orchestrating embryonic 
lymphangiogenesis considerably expands 
our understanding of the relatively small 
repertoire of molecular regulators controlling this process. More-
over, the conserved phenotypic series of mice is the first genetic, in 
vivo data to our knowledge confirming that RAMP2 interaction 
with calcrl is required for AM signaling during embryonic devel-
opment. Therefore, further characterization of AM signaling and 
its pharmacological modulation via RAMP2-CLR effectors might 
lead to novel therapeutic strategies for the treatment of lymph-
edema or inhibition of tumor metastasis.
Methods
An expanded Methods section can be found in Supplemental Methods.
Animals. The generation and characterization of mice with targeted dele-
tions of the AM, calcrl, and RAMP2 genes has been described previously 
(34–36). Gene targeting for the AM, calcrl, and RAMP2 genes was performed 
with targeting vectors and ES cells of the SvEv129/6-TC1 background. Chi-
meric male mice were then bred to SvEv129/6-TC1 female mice in order to 
establish completely isogenic colonies. In the case of RAMP2, we have pre-
viously reported that on the SvEv129/6-TC1 isogenic background, there 
are profound fertility defects (34). These fertility defects are rescued on an 
F1 (SvEv129/6-TC1:C57Bl6) background, and so animals derived from F1 
intercrosses were used for analysis in the current study.
To generate calcrlFlox/Flox mice, a calcrl floxed targeting vector was generat-
ed using a 129S6/SvEv phage clone (described in ref. 36) containing exons 
3–9 of the calcrl gene. loxP sites were inserted outside of exons 5 and 6. 
The long arm of homology included exons 7, 8, and 9, while the short arm 
included exons 3 and 4. Standard gene targeting methods were utilized to 
generate ES cells and mice with the floxed calcrl allele. Briefly, E14 ES cells 
were electroporated with the linearized targeting vector shown in Figure 
2A. After positive (G418) and negative (ganciclovir) selection, 7 positive ES 
cell clones were identified from 96 selected clones. Primers p1 and p4 were 
used for PCR-based screening of ES cells and primers p2, p3, and p4 were 
used for genotyping of mice (Figure 2A and Supplemental Figure 6). Male 
chimeric mice that transmitted the targeted allele were bred to C57BL/6J 
Figure 10
Model for role of AM signaling in lymphan-
giogenesis. Preferential upregulation of AM 
signaling genes in LECs leads to robust AM 
signaling and enhanced activation of ERK 
phosphorylation in lymphatic versus blood 
endothelial cells, which is essential for main-
taining normal lymphatic vessel proliferation 
from E14.5 to birth.
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females, and homozygous calcrlFlox/Flox mice were generated. Targeting was 
confirmed by Southern blotting using a probe indicated in Figure 2A.
B6.Xcg-Tg (tek-cre)12Flv/J (Tie2Cre) mice were obtained from the Jack-
son Laboratory. Endothelium-specific calcrl-null embryos were gener-
ated by crossing calcrl+/– female mice to Tie2Cre+ male mice. The resulting 
calcrl+/–Tie2Cre+ animals were then bred to calcrlFlox/Flox mice, resulting in 
experimental animals for this study.
For all studies, littermate controls were used. The day of the vaginal plug 
was E0.5. All experiments were approved by the Institutional Animal Care 
and Use Committee of the University of North Carolina at Chapel Hill.
Antibodies and growth factors. The following primary antibodies were used 
in this study: rat anti-mouse CD31 (PECAM) monoclonal (BD Biosci-
ences), rabbit anti-Prox1 (Chemicon), monoclonal anti–α–smooth muscle 
actin clone 1A4 (Sigma-Aldrich), goat anti-mouse VEGFR3 (R&D Sys-
tems), mouse anti–phospho-ERK1/2 (p44/42) antibody (Thr202/Tyr204), 
and rabbit anti-ERK antibody (Cell Signaling Technology). F-actin was 
stained with FITC-phalloidin (Sigma-Aldrich), and nuclei were stained 
with Hoechst 33258 (Sigma-Aldrich). Human AM and human AM22–52 
were purchased from American Peptide, PD98057 from Sigma-Aldrich, 
and recombinant human VEGFA from Pierce Biotechnology.
In vivo proliferation assay. Pregnant females were injected intraperitoneally 
with 100 μg/g body weight BrdU (Sigma-Aldrich). After 1 hour, mice were 
euthanized and embryos recovered for immunohistochemistry as described 
in Supplemental Methods. BrdU-positive cells were detected with the BrdU 
staining kit (Zymed) followed by staining in Mayer hematoxylin. Percent 
proliferative cells was determined by blinded quantitation of BrdU-positive 
cells in the lymphatic or vascular endothelium divided by total hematoxy-
lin-stained nuclei. Data were analyzed using the 2-tailed Student’s t test 
assuming unequal variance. A P value < 0.05 was considered significant.
High-resolution, 3D OPT. Whole mount immunofluorescence OPT was per-
formed by BIOPTONICS following the manufacturer’s protocol. Briefly, 
E13.5 (PECAM) and E14.5 (VEGFR3) embryos were fixed in DENTS fixa-
tive overnight, permeabilized in acetone, and washed with PBST. Embryos 
were incubated in primary antibodies and 5% goat serum, 1% BSA, and 
1% DMSO in PBST for 8–10 days. Specimens were washed in multiple 
changes of PBST for up to 4 days, and secondary antibodies in PBST were 
added. After 8 days, embryos were washed in PBST followed by PBS and 
then imaged by BIOPTONICS OPT scanner 3001 (MRC Technology).
Cell culture. HUVECs were obtained from Lonza and maintained in 
endothelial cell medium provided by the supplier and used at passages 
3–7. HMVEC-dLys (product no. CC-2810) were purchased from Lonza and 
maintained in endothelial cell medium provided by the supplier and used 
at passages 3–7. Culture media was changed every 2–3 days, and cells were 
passed when they achieved 90% confluency.
In vitro proliferation assay. Cell proliferation was measured using a modi-
fied MTS assay as previously described (58). Briefly, HMVEC-dLys and 
HUVECs were plated at 8 × 104 cells/ml on a 96-well plate. After 24 hours 
in normal growth conditions, media was changed to basic medium con-
taining 0.5% FBS for 24 hours. Cells were then treated with appropriate 
concentrations of peptide (AM or VEGFA in replicates of 5) under low-
serum conditions for 48 hours, at which point 20 μl of MTS tetrazolium 
compound (CellTiter 96Aquesous; Promega) was added to each well and 
incubation was continued for 3 hours. Absorbance at 490 nm was recorded, 
and background was corrected by subtracting the average absorbance 
observed in wells containing no cells. Percent proliferation defined as the 
corrected absorbance in treated samples divided by corrected absorbance 
of untreated samples.
For total cell count determinations, HMVEC-dLys and HUVECs were 
plated at 2 × 105 cells/ml in each well of 6-well plates. After 24 hours in 
normal growth conditions, media was changed to basic medium con-
taining 0.5% FBS for 24 hours. Cells were then treated with 10 nm of 
AM peptide under low-serum conditions for 48 hours. At 48 hours, the 
cells were lifted off the plate by application of 0.25% trypsin (Gibco; 
Invitrogen) and counted visually with a hemocytometer. Percent prolif-
eration was a measure of treated samples divided by untreated samples. 
Experiments were performed in duplicate, and data are representative of 
3 separate experiments.
Prox1 transfections. For electroporation of HUVECs and HMVEC-dLys, the 
plasmid pFlag, either empty or containing full-length hProx1 (59), a kind 
gift from Eckard Truter, Karolinska Institute, Sweden, were electroporated 
in triplicate. HUVECs or HMVEC-dLys (1 × 106) were electroporated using 
the HUVEC Nucleofector kit (Amaxa). Twenty-four hours after transfec-
tion, RNA was generated for quantitative RT-PCR as described above.
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